Biosimilar adalimumab regulatory update

FDA’s Arthritis Advisory Committee will meet on July 12 to discuss a BLA from Amgen for ABP 501, a biosimilar of autoimmune drug Humira adalimumab from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.). The ac...